The Obesity ETF (SLIM) seeks investment results that correspond generally, before fees and expenses, to the performance of the Solactive Obesity Index.
ABOUT THIS ETF
Thematic ETFs provide investors with the opportunity to invest in companies that may benefit from the transformational forces changing our future. The Obesity ETF seeks exposure to companies globally that could benefit as they fight the global obesity epidemic. Such companies could include biotechnology, pharmaceutical, health care and medical device companies focused on obesity and obesity-related disease such as diabetes, high blood pressure, cholesterol, heart disease, stroke and sleep apnea. The ETF also includes companies focused on weight-loss programs, supplements and plus-size apparel.
WHY INVEST IN THIS ETF
Humans Are Getting Heavier
Obesity rates are predicted to steadily increase until 2030. Global obesity levels are expected to be highest in the United States, Mexico and England, where 47%, 39% and 35% of the population, respectively, are projected to be obese by 2030.
OECD Analysis of National Health Survey Data. As of 2017.
Rising Costs Spurring Action
As obesity and overweight levels rise, so do the enormous direct and indirect medical expenditures for treatment and prevention which globally are estimated at $2 trillion annually – creating increased pressure to tackle the issue.
National Center for Weight & Wellness at George Washington University and the McKinsey Global Institute 4/2015.
Targeted Thematic Exposure
The strategy provides investors with the opportunity to invest in companies globally that could benefit as they fight the global obesity epidemic.
OLD | ORG | SLIM
Thematic investing goes beyond trendspotting to identify those transformative forces that could permanently alter our lives and behaviors, creating investment opportunities- opportunities that come from a new future shaped by meaningful change.